MENU
NEWSLETTERS
MENU
SECTIONS
OTHER
CLASSIFIEDS
CONTACT US / FAQ
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Regeneron Pharmaceuticals (NQ:REGN)

754.31 -22.94 (-2.95%)
Streaming Delayed Price Updated: 11:06 AM EDT, Apr 2, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 236,649
Open 767.04
Bid (Size) 753.64 (40)
Ask (Size) 755.98 (120)
Prev. Close 777.25
Today's Range 747.00 - 770.11
52wk Range 476.49 - 821.11
Shares Outstanding 91,779,465
Dividend Yield 0.50%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Biotech Defies Gravity: Sarepta and Corcept Lead Midday Healthcare Rally Amidst Market Volatility
In a trading session characterized by sharp declines across the technology and industrial sectors, the healthcare industry emerged as a resilient fortress on March 31, 2026. While the broader S&P 500... 
Via MarketMinute
Topics Economy Intellectual Property Stocks
News headline image
Regeneron Pharmaceuticals: A Strong Contender in the Biotech Arena ↗
Could Regeneron Pharmaceuticals be the next big winner in biotech? Join us as we break down the company's strengths, challenges, and future potential in this insightful episode. 
Via The Motley Fool

Performance

YTD
-2.8%
-2.8%
1 Month
-4.6%
-4.6%
3 Month
-2.3%
-2.3%
6 Month
+25.7%
+25.7%
1 Year
+22.3%
+22.3%

More News

Read More
News headline image
Eli Lilly Shares Slip Despite Positive Eczema Trial Results: Why the Market Reacted Coolly
Via MarketMinute
News headline image
AstraZeneca (AZN) Shares Rally After Breakthrough Chronic Lung Disease Trial Results
Via MarketMinute
Topics Intellectual Property
News headline image
Is Regeneron a Multimillionaire-Maker Stock? ↗
Via The Motley Fool
Topics Intellectual Property
News headline image
Kodiak Sciences Surges 19% as Phase 3 GLOW2 Trial Delivers Vital Win for Diabetic Retinopathy Treatment
Via MarketMinute
News headline image
The Brain Barrier Broken: Inside Denali Therapeutics’ Landmark FDA Approval of AVLAYAH
Via Finterra
Topics Economy Initial Public Offering
News headline image
Regeneron to Report First Quarter 2026 Financial and Operating Results and Host Conference Call and Webcast on April 29, 2026
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Dupixent® (dupilumab) Approved in Japan as the First Targeted Medicine to Treat Adults with Bullous Pemphigoid (BP)
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
This $91 Million Position Signals Conviction in a Biotech Stock Eyeing FDA Decision This Year ↗
Via The Motley Fool
News headline image
Is Eli Lilly's Weight Loss Empire in Trouble? ↗
Via The Motley Fool
News headline image
3 Profitable Stocks We Think Twice About
Via StockStory
News headline image
In 2036, Investors Will Regret Not Loading Up on This Multibagger in the Making ↗
Via The Motley Fool
Topics Earnings
News headline image
Olatorepatide Obesity Treatment Licensed by Regeneron Demonstrates Positive Phase 3 Results in Chinese Patients
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
2 Underrated Weight Loss Stocks to Buy Now ↗
Via The Motley Fool
Topics Intellectual Property
News headline image
1 Nasdaq 100 Stock to Consider Right Now and 2 We Brush Off
Via StockStory
News headline image
Regeneron Announces Investor Conference Presentation
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
2 Biotech Giants to Buy in 2026 ↗
Via The Motley Fool
Topics Intellectual Property
News headline image
Dupixent® (dupilumab) Recommended for EU Approval to Treat Chronic Spontaneous Urticaria (CSU) in Young Children with Ongoing Symptoms Despite Treatment
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Regeneron Renews Sponsorship of the Regeneron Science Talent Search Through 2036, Committing an Additional $150 Million to Empower the Next Generation of Science and Technology Leaders
From Society For Science
Via GlobeNewswire
News headline image
2 Reasons Regeneron Stock Could Crush the Market for the Next 10 Years ↗
Via The Motley Fool
Topics Intellectual Property
News headline image
Dupixent® (dupilumab) Approved in the U.S. as the First and Only Medicine for Allergic Fungal Rhinosinusitis (AFRS)
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
1 No-Brainer Biotech Stock To Buy Today and Never Sell ↗
Via The Motley Fool
News headline image
Garetosmab Biologics License Application Accepted for FDA Priority Review for the Treatment of Fibrodysplasia Ossificans Progressiva (FOP)
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Sanofi Tightens Grip on Ocular Therapeutix with Revised Bid as Pivotal SOL-1 Trial Results Loom
Via MarketMinute

Frequently Asked Questions

Is Regeneron Pharmaceuticals publicly traded?
Yes, Regeneron Pharmaceuticals is publicly traded.
What exchange does Regeneron Pharmaceuticals trade on?
Regeneron Pharmaceuticals trades on the Nasdaq Stock Market
What is the ticker symbol for Regeneron Pharmaceuticals?
The ticker symbol for Regeneron Pharmaceuticals is REGN on the Nasdaq Stock Market
What is the current price of Regeneron Pharmaceuticals?
The current price of Regeneron Pharmaceuticals is 754.31
When was Regeneron Pharmaceuticals last traded?
The last trade of Regeneron Pharmaceuticals was at 04/02/26 11:06 AM ET
What is the market capitalization of Regeneron Pharmaceuticals?
The market capitalization of Regeneron Pharmaceuticals is 69.23B
How many shares of Regeneron Pharmaceuticals are outstanding?
Regeneron Pharmaceuticals has 69B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story